Primerica (PRI) investor relations material

Executive summary

• Total revenues for Q2 2026 increased 9% year-over-year to $865.1 million, driven by higher commissions and fees in the Investment and Savings Products segment and growth in net premiums in Term Life Insurance.

• Adjusted operating revenues rose 8% and adjusted net operating income increased 11% year-over-year, with adjusted operating EPS up 17% to $6.41, aided by tax benefits from a tax equity investment.

• Net income rose 13% year-over-year to $202.3 million, with diluted EPS up to $6.45 from $5.40.

• Investment & Savings Products segment saw record client demand, with revenues up 21%, pre-tax income up 31%, and sales up 23% to $4.4 billion.

• Life-licensed sales force totaled 148,612 at quarter-end, down 3% year-over-year.

Financial highlights

• Assets under management reached a record $140 billion, up 16% from June 30, 2025, with $397 million in net inflows.

• Net premiums increased 1%; adjusted direct premiums up 3% year-over-year.

• Consolidated insurance and other operating expenses were $166 million, up 8% year-over-year, mainly due to higher variable costs, compensation, and technology investments.

• Return on adjusted equity was 33.1%, up 90 basis points year-over-year.

• Effective income tax rate was 21.7%, down from 23.9% in the prior year period, due to federal tax benefits from a new tax equity investment.

Outlook and guidance

• Management expects continued growth in the Investment and Savings Products segment, supported by favorable demographics and strong equity markets.

• Full year sales force size projected to be flat to down 2% versus 2025; issued life policies expected to decline by mid-single digits, with improvement anticipated in the second half.

• Full year ISP sales projected to increase 10%-15% in 2026.

• Expense growth forecasted at 10%-12% in Q3 and 6%-7% in Q4, with full year expense growth of 7%-8%.

• The company anticipates sufficient liquidity and capital to support operations and growth over the next 12 months.